HomeAI · summaries
Storia in 2 fonti
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy - Innate
Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
- ·
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
